Scholarlink

<p>A novel series of triazole alcohols containing an indole-3-methyl(phenyl)a- mino side chain have been synthesized as derivatives of fluconazole. The title compounds were synthesized via the ring-open reaction of epoxide with various N-aryl indole-3-methylamine. Compound <b>C04</b> exhibited significant inhibitory activity against fluconazole-resistant <i>Candida albicans</i> (ATCC-14053) with an MIC<sub>50</sub> of 2.31 μM. Notably, compound <b>C08</b> displayed potent inhibition against seven fungal pathogens including two clinically isolated fluconazole-resistant strains. The time-kill assays demonstrated that compounds C04 and C08 exhibited significant growth inhibitory effects against <i>Candida albicans</i> ATCC 14053. Further studies confirmed their potent inhibitory activity against <i>C. albicans</i> biofilm development. Cytotoxicity evaluation demonstrated that both compounds exhibited favorable safety profiles. These results indicate that <b>C04</b> and <b>C08</b> are promising antifungal drug candidates, providing novel therapeutic strategies to combat clinically resistant fungal infections.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis and biological evaluation of triazole alcohols containing an indole-3-methyl(phenyl)amino side chain against fluconazole-resistant Candida albicans

  • 期刊论文

  • 发表日期：

    2025年9月20日

查看全文
  • Zefei Fan,
  • Lijiao Yang,
  • Jidong Wang,
  • Yafei Hou,
  • Fei Zou,
  • Tianyu Zhang,
  • Yongyan Fu,
  • Yue Zhang,
  • Ruirui Wang,
  • Shichong Yu,
  • Guanghui Ni

摘要

A novel series of triazole alcohols containing an indole-3-methyl(phenyl)a- mino side chain have been synthesized as derivatives of fluconazole. The title compounds were synthesized via the ring-open reaction of epoxide with various N-aryl indole-3-methylamine. Compound C04 exhibited significant inhibitory activity against fluconazole-resistant Candida albicans (ATCC-14053) with an MIC50 of 2.31 μM. Notably, compound C08 displayed potent inhibition against seven fungal pathogens including two clinically isolated fluconazole-resistant strains. The time-kill assays demonstrated that compounds C04 and C08 exhibited significant growth inhibitory effects against Candida albicans ATCC 14053. Further studies confirmed their potent inhibitory activity against C. albicans biofilm development. Cytotoxicity evaluation demonstrated that both compounds exhibited favorable safety profiles. These results indicate that C04 and C08 are promising antifungal drug candidates, providing novel therapeutic strategies to combat clinically resistant fungal infections.